Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis

BACKGROUND: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction, with some recommended treatments targeting brain-gut axis dysfunction. OBJECTIVE: To compare relative efficacy of gut-brain neuromodulators and brain-gut behaviour therapies in IBS. DESIGN: Network meta-analysis searching the medical literature to 8 February 2026 for randomised controlled trials (RCTs) of gut-brain neuromodulators or brain-gut behaviour therapies in adults with IBS. In our main analysis, we judged efficacy using dichotomous endpoints of improvement in either global IBS symptoms or abdominal pain. We pooled data with a random effects model, with efficacy reported as a pooled relative risk (RR) with 95% CIs. We ranked treatments according to P-score; the mean extent of certainty that one treatment is better than another averaged over all competing treatments. RESULTS: We identified 68 eligible RCTs (6694 participants). Compared with waiting list control, in 66 trials (6542 patients), serotonin and norepinephrine reuptake inhibitors (SNRIs) ranked first in six trials (387 patients) (RR of global IBS symptoms or abdominal pain not improving=0.49; 95% CI 0.32 to 0.75, P-score 0.95), meaning the probability that this was the most efficacious treatment was 95%. However, no trials were at low risk of bias. Tricyclic antidepressants (TCAs) ranked second in 15 trials (1519 patients) (RR=0.60; 95% CI 0.43 to 0.85, P-score 0.79) and forms of dynamic psychotherapy/emotional processing third (RR=0.62; 95% CI 0.44 to 0.87, P-score 0.75). Forms of cognitive behavioural therapy (CBT), forms of disease self-management, selective serotonin reuptake inhibitors and forms of gut-directed hypnotherapy (GDH) were also superior to waiting list control. CONCLUSION: Several gut-brain neuromodulators, especially TCAs, and brain-gut behaviour therapies, particularly forms of dynamic psychotherapy/emotional processing, CBT, disease self-management and GDH, are efficacious for IBS. However, there was possible publication bias in some analyses, and overall certainty in the evidence was low or very low for most comparisons.

Authors

Institutions

Publication Details

Journal
Gut
Published
2026-06-26
DOI
https://doi.org/10.1136/gutjnl-2026-339311
Primary Topic
Gastrointestinal motility and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis

Christopher J. Black, Vivek C. Goodoory, Alexander C. Ford, Mais Khasawneh et al.
Gut
Gastrointestinal motility and disorders
article

Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis

Christopher J. Black, Vivek C. Goodoory, Alexander C. Ford, Mais Khasawneh, Elyse R. Thakur, P Moayyedi
article en

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction, with some recommended treatments targeting brain-gut axis dysfunction. OBJECTIVE: To compare relative efficacy of gut-brain neuromodulators and brain-gut behaviour therapies in IBS. DESIGN: Network meta-analysis searching the medical literature to 8 February 2026 for randomised controlled trials (RCTs) of gut-brain neuromodulators or brain-gut behaviour therapies in adults with IBS. In our main analysis, we judged efficacy using dichotomous endpoints of improvement in either global IBS symptoms or abdominal pain. We pooled data with a random effects model, with efficacy reported as a pooled relative risk (RR) with 95% CIs. We ranked treatments according to P-score; the mean extent of certainty that one treatment is better than another averaged over all competing treatments. RESULTS: We identified 68 eligible RCTs (6694 participants). Compared with waiting list control, in 66 trials (6542 patients), serotonin and norepinephrine reuptake inhibitors (SNRIs) ranked first in six trials (387 patients) (RR of global IBS symptoms or abdominal pain not improving=0.49; 95% CI 0.32 to 0.75, P-score 0.95), meaning the probability that this was the most efficacious treatment was 95%. However, no trials were at low risk of bias. Tricyclic antidepressants (TCAs) ranked second in 15 trials (1519 patients) (RR=0.60; 95% CI 0.43 to 0.85, P-score 0.79) and forms of dynamic psychotherapy/emotional processing third (RR=0.62; 95% CI 0.44 to 0.87, P-score 0.75). Forms of cognitive behavioural therapy (CBT), forms of disease self-management, selective serotonin reuptake inhibitors and forms of gut-directed hypnotherapy (GDH) were also superior to waiting list control. CONCLUSION: Several gut-brain neuromodulators, especially TCAs, and brain-gut behaviour therapies, particularly forms of dynamic psychotherapy/emotional processing, CBT, disease self-management and GDH, are efficacious for IBS. However, there was possible publication bias in some analyses, and overall certainty in the evidence was low or very low for most comparisons.

Gut
University of North Carolina at Charlotte (US), University of Leeds (GB), Leeds Teaching Hospitals NHS Trust (GB), St James's University Hospital (GB), McMaster University (CA)
Good health and well-being
Openalex Percentile: Top 5%
Gastrointestinal motility and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.